Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice.

Kim A, Morgan K, Hasz DE, Wiesner SM, Lauchle JO, Geurts JL, Diers MD, Le DT, Kogan SC, Parada LF, Shannon K, Largaespada DA.

Blood. 2007 Feb 15;109(4):1687-91. Epub 2006 Nov 7.

2.

Leukemic potential of doubly mutant Nf1 and Wv hematopoietic cells.

Ingram DA, Wenning MJ, Shannon K, Clapp DW.

Blood. 2003 Mar 1;101(5):1984-6. Epub 2002 Oct 17.

3.

Nf1 and Gmcsf interact in myeloid leukemogenesis.

Birnbaum RA, O'Marcaigh A, Wardak Z, Zhang YY, Dranoff G, Jacks T, Clapp DW, Shannon KM.

Mol Cell. 2000 Jan;5(1):189-95.

4.

Tie2-Cre-induced inactivation of a conditional mutant Nf1 allele in mouse results in a myeloproliferative disorder that models juvenile myelomonocytic leukemia.

Gitler AD, Kong Y, Choi JK, Zhu Y, Pear WS, Epstein JA.

Pediatr Res. 2004 Apr;55(4):581-4. Epub 2004 Jan 22.

PMID:
14739366
5.

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.

Le DT, Kong N, Zhu Y, Lauchle JO, Aiyigari A, Braun BS, Wang E, Kogan SC, Le Beau MM, Parada L, Shannon KM.

Blood. 2004 Jun 1;103(11):4243-50. Epub 2004 Feb 24.

6.

Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines.

Zhang YY, Vik TA, Ryder JW, Srour EF, Jacks T, Shannon K, Clapp DW.

J Exp Med. 1998 Jun 1;187(11):1893-902.

7.

Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.

Chan RJ, Leedy MB, Munugalavadla V, Voorhorst CS, Li Y, Yu M, Kapur R.

Blood. 2005 May 1;105(9):3737-42. Epub 2005 Jan 11.

8.

Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.

Wiesner SM, Geurts JL, Diers MD, Bergerson RJ, Hasz DE, Morgan KJ, Largaespada DA.

Am J Hematol. 2011 Jul;86(7):579-85. doi: 10.1002/ajh.22035.

9.

Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.

Sachs Z, Been RA, DeCoursin KJ, Nguyen HT, Mohd Hassan NA, Noble-Orcutt KE, Eckfeldt CE, Pomeroy EJ, Diaz-Flores E, Geurts JL, Diers MD, Hasz DE, Morgan KJ, MacMillan ML, Shannon KM, Largaespada DA, Wiesner SM.

Haematologica. 2016 Oct;101(10):1190-1199. Epub 2016 Jul 14.

10.

Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders.

Miles DK, Freedman MH, Stephens K, Pallavicini M, Sievers EL, Weaver M, Grunberger T, Thompson P, Shannon KM.

Blood. 1996 Dec 1;88(11):4314-20.

11.

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K.

J Clin Invest. 2013 Jan;123(1):335-9. doi: 10.1172/JCI63193. Epub 2012 Dec 10. Erratum in: J Clin Invest. 2016 Jan;126(1):404.

12.

Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.

Chan G, Kalaitzidis D, Usenko T, Kutok JL, Yang W, Mohi MG, Neel BG.

Blood. 2009 Apr 30;113(18):4414-24. doi: 10.1182/blood-2008-10-182626. Epub 2009 Jan 29.

13.

Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1.

Side LE, Emanuel PD, Taylor B, Franklin J, Thompson P, Castleberry RP, Shannon KM.

Blood. 1998 Jul 1;92(1):267-72.

14.

Deficiency of β Common Receptor Moderately Attenuates the Progression of Myeloproliferative Neoplasm in NrasG12D/+ Mice.

Zhang J, Ranheim EA, Du J, Liu Y, Wang J, Kong G, Zhang J.

J Biol Chem. 2015 Jul 31;290(31):19093-103. doi: 10.1074/jbc.M115.653154. Epub 2015 Jun 16.

15.

Juvenile myelomonocytic leukemia.

Emanuel PD.

Curr Hematol Rep. 2004 May;3(3):203-9. Review.

PMID:
15087069
16.

Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy.

Liu YL, Yan Y, Webster C, Shao L, Lensing SY, Ni H, Feng W, Colorado N, Pathak R, Xiang Z, Hauer-Jensen M, Li S, Zhou D, Emanuel PD.

Blood. 2016 Apr 14;127(15):1912-22. doi: 10.1182/blood-2015-05-646216. Epub 2016 Jan 13.

17.

Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia.

Largaespada DA, Brannan CI, Jenkins NA, Copeland NG.

Nat Genet. 1996 Feb;12(2):137-43.

PMID:
8563750
18.

Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk.

Staser K, Park SJ, Rhodes SD, Zeng Y, He YZ, Shew MA, Gehlhausen JR, Cerabona D, Menon K, Chen S, Sun Z, Yuan J, Ingram DA, Nalepa G, Yang FC, Clapp DW.

J Clin Invest. 2013 Jan;123(1):329-34. doi: 10.1172/JCI66167. Epub 2012 Dec 10.

19.

Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.

Flotho C, Steinemann D, Mullighan CG, Neale G, Mayer K, Kratz CP, Schlegelberger B, Downing JR, Niemeyer CM.

Oncogene. 2007 Aug 23;26(39):5816-21. Epub 2007 Mar 12.

PMID:
17353900
20.

Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.

Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K.

Nat Genet. 1996 Feb;12(2):144-8.

PMID:
8563751

Supplemental Content

Support Center